Latest News and Press Releases
Want to stay updated on the latest news?
-
PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with...
-
Seyond reports strong post-IPO commercial momentum, with growing adoption across autonomous mobility, robotics, and intelligent sensing applications.
-
CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.
-
基于全球III期MANEUVER研究的积极数据，中国国家药品监督管理局（NMPA）批准了贝捷迈®（盐酸匹米替尼胶囊）的全球首个新药上市申请，也是中国首个自主研发的腱鞘巨细胞瘤（TGCT）系统性治疗药物。默克作为我们的合作伙伴，拥有贝捷迈®在全球的商业化权益。贝捷迈®是和誉医药自主研发的1类新药，上市申请（NDA）获受理后仅6个多月即实现零发补批准。期间顺利通过国家药监局核查中心（CFDI）首次赴海...
-
Based on the positive global Phase III MANEUVER study, the NMPA has granted the world's first regulatory approval for pimicotinib.
-
The current indications under development are strategically positioned within the vast dermatology market, including AD, vitiligo, PN, CSU, and more.
-
ROCKVILLE, Md. and SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage,...
-
HANGZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Following the successful completion of a rigorous driving challenge in Melbourne and Sydney between December 9 and 10 2025, Geely Auto is proud to...
-
HANGZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Tras la exitosa finalización de un riguroso desafío de conducción en Melbourne y Sídney entre el 9 y el 10 de diciembre de 2025, Geely Auto se...
-
— First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI...